David B Cody Selected Research

Ro 25-1553

2/2005

Activation of the vasoactive intestinal peptide 2 receptor modulates normal and atrophying skeletal muscle mass and force.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

David B Cody Research Topics

Disease

6	Atrophy 03/2008 - 05/2002
3	Thrombosis (Thrombus) 01/2022 - 01/2018
1	Cardiovascular Diseases (Cardiovascular Disease) 01/2022
1	Atherosclerosis 01/2019
1	Hemorrhage 01/2018
1	Heart Diseases (Heart Disease) 01/2018
1	Wasting Syndrome (Wasting Disease) 12/2005
1	Hypertrophy 05/2002

Drug/Important Bio-Agent (IBA)

3	trimethyloxamine (trimethylamine N-oxide)IBA 01/2022 - 01/2018
2	Carnitine (L-Carnitine)FDA LinkGeneric 01/2022 - 01/2019
2	Adrenal Cortex Hormones (Corticosteroids)IBA 02/2005 - 10/2003
1	gamma-butyrobetaine (butyrobetaine)IBA 01/2019
1	trimethylamineIBA 01/2019
1	Estrogens (Estrogen)FDA Link 03/2008
1	Estrogen ReceptorsIBA 03/2008
1	G-Protein-Coupled Receptors (Receptors, G Protein Coupled)IBA 03/2008
1	Estrogen Receptor alphaIBA 03/2008
1	Estrogen Receptor betaIBA 03/2008
1	Phosphodiesterase 4 InhibitorsIBA 12/2005
1	Type 4 Cyclic Nucleotide PhosphodiesterasesIBA 12/2005
1	Ro 25-1553IBA 02/2005
1	UrocortinsIBA 11/2003
1	Adrenergic beta-Agonists (beta-Adrenergic Agonists)IBA 05/2002
1	ClenbuterolIBA 05/2002

Therapy/Procedure

2	Denervation 02/2005 - 05/2002
1	Transplantation 01/2022